PREV Stock Overview
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PreveCeutical Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.03 |
| 52 Week Low | CA$0.015 |
| Beta | 1.06 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | 0% |
| 5 Year Change | -58.33% |
| Change since IPO | -81.62% |
Recent News & Updates
Shareholder Returns
| PREV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.1% |
| 1Y | 0% | 58.0% | 3.6% |
Return vs Industry: PREV underperformed the Canadian Pharmaceuticals industry which returned 46% over the past year.
Return vs Market: PREV underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
| PREV volatility | |
|---|---|
| PREV Average Weekly Movement | 25.8% |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: PREV has not had significant price volatility in the past 3 months.
Volatility Over Time: PREV's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Stephen Van Deventer | www.preveceutical.com |
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products.
PreveCeutical Medical Inc. Fundamentals Summary
| PREV fundamental statistics | |
|---|---|
| Market cap | CA$13.38m |
| Earnings (TTM) | -CA$517.52k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-25.9x
P/E RatioIs PREV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PREV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$517.52k |
| Earnings | -CA$517.52k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00097 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -70.0% |
How did PREV perform over the long term?
See historical performance and comparison